TY - JOUR
T1 - High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas
AU - Braggio, Esteban
AU - Keats, Jonathan
AU - Leleu, Xavier
AU - Wier, Scott Van
AU - Jimenez-Zepeda, Victor Hugo
AU - Schop, Roelandt
AU - Chesi, Marta
AU - Barrett, Michael
AU - Stewart, Alexander Keith
AU - Dogan, Ahmet
AU - Bergsagel, Peter Leif
AU - Ghobrial, Irene
AU - Fonseca, Rafael
N1 - Funding Information:
This work was funded by the International Waldenstrom's Macroglobulinemia Foundation. We thank Chris Gooden and Michael Bittner for helpful assistance. E.B. is supported by IWMF 2S grant from the IWMF. J.J.K. is supported by a MMRF Fellowship and the Gene and Mary-Lou Kurtz fellowship in myeloma. P.L.B. is supported by R01-AG020686 and SPORE P50-CA100707-01. R.F. is supported by R01-CA83724-01, SPORE P50-CA100707-01 and P01-CA62242 from the National Cancer Institute, and the Donaldson Charitable Trust Fund. R.F. is a Clinical Investigator of the Damon Runyon Cancer Research Fund.
Funding Information:
E.B. is supported by IWMF 2S grant from the International Waldenström’ s Macroglobulinemia Foundation. J.J.K. is supported by a MMRF Fellowship and the Gene and Mary-Lou Kurtz fellowship in myeloma. P.L.B. is supported by R01-AG020686 and SPORE P50-CA100707-01. R.F. is supported by CA 972 74, R01-CA83724-01, SPORE P50-CA100707-01 and P01-CA62242 from the National Cancer Institute, and the Donaldson Charitable Trust Fund. R.F. is a Clinical Investigator of the Damon Runyon Cancer Research Fund.
PY - 2009
Y1 - 2009
N2 - Cytogenetic analyses have been historically limited in Waldenström's macroglobulinemia (WM) by the difficulty to obtain tumor metaphases. Thus, few recurrent karyotypic abnormalities have been reported and the molecular consequences of these imbalances are largely unknown. We used an array-based comparative genomic hybridization approach to better characterize the recurrent chromosome abnormalities associated with WM pathogenesis and to compare them with the publicly available findings in other B-cell neoplasias. The majority of the recurrent chromosome abnormalities identified in WM were shared with marginal zone lymphomas (MZL), as deletions of 6q23 and 13q14 and gains of 3q13-q28, 6p and 18q. On the other hand, gains of 4q and 8q were recurrently identified in WM but have not been described as being common abnormalities in MZL. The genetic consequences of these specific abnormalities remain elusive and further studies are critical to refine the search and to precise the molecular pathways affected by these abnormalities.
AB - Cytogenetic analyses have been historically limited in Waldenström's macroglobulinemia (WM) by the difficulty to obtain tumor metaphases. Thus, few recurrent karyotypic abnormalities have been reported and the molecular consequences of these imbalances are largely unknown. We used an array-based comparative genomic hybridization approach to better characterize the recurrent chromosome abnormalities associated with WM pathogenesis and to compare them with the publicly available findings in other B-cell neoplasias. The majority of the recurrent chromosome abnormalities identified in WM were shared with marginal zone lymphomas (MZL), as deletions of 6q23 and 13q14 and gains of 3q13-q28, 6p and 18q. On the other hand, gains of 4q and 8q were recurrently identified in WM but have not been described as being common abnormalities in MZL. The genetic consequences of these specific abnormalities remain elusive and further studies are critical to refine the search and to precise the molecular pathways affected by these abnormalities.
KW - ACGH
KW - Comparative genomic analysis
KW - Waldenström
UR - http://www.scopus.com/inward/record.url?scp=67649510148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649510148&partnerID=8YFLogxK
U2 - 10.3816/CLM.2009.n.009
DO - 10.3816/CLM.2009.n.009
M3 - Article
C2 - 19362969
AN - SCOPUS:67649510148
SN - 1557-9190
VL - 9
SP - 39
EP - 42
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
IS - 1
ER -